You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handout How to Safely Take Your Oral Anti-Cancer Medication.

Displaying Drugs List

8 Items
Other Name(s): Caprelsa®
Funding:
Exceptional Access Program
  • vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Jun 2019
Other Name(s): Zelboraf ®
Funding:
Exceptional Access Program
  • vemURAFenib - For 1st line and 2nd line monotherapy treatment of BRAF V600 mutation-positive unresectable stage IIIC or IV melanoma or metastatic disease according to specific criteria.
  • vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma
Jun 2019
Other Name(s): Venclexta®
Funding:
Exceptional Access Program
  • Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma according to clinical criteria.
Jun 2019
Other Name(s): Velban® (multiple brands available)
May 2018
Other Name(s): Oncovin® (multiple brands available)
Nov 2017
Other Name(s): Navelbine® (multiple brands available)
Funding:
New Drug Funding Program
  • Vinorelbine - Non-Small Cell Lung Cancer (NSCLC)
  • Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
  • Vinorelbine - Metastatic Breast Cancer
May 2018
Other Name(s): Erivedge®
Funding:
Exceptional Access Program
  • vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Jun 2019
Other Name(s): Zolinza®
Jun 2019